Bio-Techne Corporation – NASDAQ:TECH

Add to watchlist

$54.8

-18.18

-24.91%

Market closed

Open in 21 minutes

-5.60%

month

-5.60%

quarter

-6.65%

year

Market Cap	11.47B
Enterprise value	11.80B

P/E	76.76
EV/Sales	10.07
EV/EBITDA	33.93
Price/Sales	9.89
Price/Book	5.40
PEG ratio	16.37
EPS	1.63

Revenue	1.18B
EBITDA	434.36M
Income	256.28M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	12.86%
Oper. margin	19.54%
Gross margin	65.7%
EBIT margin	19.54%
EBITDA margin	36.59%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Bio-Techne Stock Forecast

M Q Y

Last Year

$82.33

Potential upside: 50.24%

Analysts Price target
Financials & Ratios estimates

Bio-Techne Corporation (NASDAQ:TECH): Profit margin
Jun 2022	288.22M	61.52M	21.35%
Mar 2023	294.14M	70.21M	23.87%
Jun 2023	301.32M	75.48M	25.05%
Mar 2024	303.42M	49.05M	16.17%

Bio-Techne Corporation (NASDAQ:TECH): Earnings per share (EPS)
2023-05-03	0.53	0.49

Bio-Techne Corporation (NASDAQ:TECH): Payout ratio
Payout ratio	33.48%

Bio-Techne Corporation (NASDAQ:TECH): Dividend Yield
2020	0.48%
2021	0.28%
2022	0.37%
2023	0.39%
2024	0.45%

Bio-Techne Corporation (NASDAQ:TECH): Debt to assets
Dec 2022	2363401000	536.29M	22.69%
Mar 2023	2599696000	710.01M	27.31%
Jun 2023	2638692000	672.17M	25.47%
Mar 2024	2721170000	706.79M	25.97%

Bio-Techne Corporation (NASDAQ:TECH): Cash Flow
Jun 2022	102.71M	-18.57M	-65.72M
Mar 2023	50.53M	-241.09M	150.83M
Jun 2023	83.39M	-4.75M	-24.22M
Mar 2024	80.98M	-16.44M	-52.41M

Bio-Techne alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Bio-Techne Social Media Accounts

Bio-Techne Corporation (NASDAQ:TECH): Followers count
May 2025	1583
Jul 2025	1602
Aug 2025	1594

Google Trends

Bio-Techne Services

Bio-Techne Corporation (NASDAQ:TECH): Google Trends - Bio-Techne Services
11 Jun 2023	40	58
18 Jun 2023	35	52
25 Jun 2023	42	61
2 Jul 2023	43	62
9 Jul 2023	49	69
16 Jul 2023	47	60
23 Jul 2023	42	57
30 Jul 2023	49	69
6 Aug 2023	51	67
13 Aug 2023	50	61
20 Aug 2023	49	58
27 Aug 2023	42	54
3 Sep 2023	47	58
10 Sep 2023	52	66
17 Sep 2023	47	49
24 Sep 2023	54	67
1 Oct 2023	62	64
8 Oct 2023	59	55
15 Oct 2023	41	45
22 Oct 2023	31	45

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Bio-Techne Corporation (NASDAQ:TECH): Job openings
Sep 2023	127
Oct 2023	103
Nov 2023	128
Dec 2023	111
Jan 2024	110
Feb 2024	149
Apr 2024	157
May 2024	126
Jun 2024	114
Jul 2024	121

Bio-Techne
Employees

Bio-Techne Corporation (NASDAQ:TECH): Employee count
Sep 2023	3,050
Oct 2023	3,050
Nov 2023	3,050
Dec 2023	3,200
Jan 2024	3,200
Feb 2024	3,200
Mar 2024	3,200
Apr 2024	3,200
May 2024	3,200
Jun 2024	3,200
Jul 2024	3,200

Bio-Techne
Hedge Funds Holdings Q3 2022

82.95% -7.01%

of TECH is owned by hedge funds

479 -49

hedge funds hold TECH stock

34.03M -2.82M

shares is hold by hedge funds

TECH hedge funds holdings changes

Bio-Techne Corporation (NASDAQ:TECH): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	0	322
Jul 2023	0	80000
Aug 2023	0	8939
Mar 2024	0	10400
May 2024	0	4000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	8 Jul 2024	HIGGINS JOHN L director	Stock Options (Right to Buy)	6,000	$22.95	$137,700
Option	8 Jul 2024	HIGGINS JOHN L director	Common Stock	6,000	$22.95	$137,700
Option	14 May 2024	HIGGINS JOHN L director	Stock Options (Right to Buy)	4,000	$22.95	$91,800
Option	14 May 2024	HIGGINS JOHN L director	Common Stock	4,000	$22.95	$91,800
Sale	14 May 2024	HIGGINS JOHN L director	Common Stock	4,000	$83.84	$335,376
Option	3 Apr 2024	BOHNEN SHANE officer: SVP - General Counsel officer: SVP - General Counsel	Restricted Stock Units	2,259	N/A	N/A
Option	3 Apr 2024	BOHNEN SHANE officer: SVP - General Counsel officer: SVP - General Counsel	Common Stock	2,259	N/A	N/A
Sale	7 Mar 2024	NUSSE ROELAND director director	Common Stock	10,400	$76.98	$800,623
Option	19 Dec 2023	HIPPEL JAMES officer: CFO	Stock Options (Right to Buy)	47,289	$31.26	$1,478,254
Option	19 Dec 2023	HIPPEL JAMES officer: CFO	Common Stock	47,289	$31.26	$1,478,254

Status	Patent	Filling date	Issue date
Application	Application SURFACE PLASMON RESONANCE SENSOR CHIP HAVING SENSOR SURFACE CAPABLE OF CAPTURING MULTIPLE SPECIES OF ANTIBODIES AND METHOD OF MAKING Filling date: 17 Feb 2022 Issue date: 2 Jun 2022	17 Feb 2022	2 Jun 2022
Application	Application WNT/SFRP COMPLEXES, WNT-CONTAINING COMPOSITIONS, WNT-EXPRESSING CELLS, AND METHODS OF MAKING, PURIFYING, AND USING SAME Filling date: 18 Jun 2021 Issue date: 9 Dec 2021	18 Jun 2021	9 Dec 2021
Grant	Grant Utility: Wnt/sFRP complexes, Wnt-containing compositions, Wnt-expressing cells, and methods of making, purifying, and using same Filling date: 9 Oct 2018 Issue date: 29 Jun 2021	9 Oct 2018	29 Jun 2021
Application	Application METHODS AND KITS FOR DETECTING O-GlcNAc SITES USING B3GALNT2 AND OGT Filling date: 17 Apr 2019 Issue date: 15 Apr 2021	17 Apr 2019	15 Apr 2021
Application	Application HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES TO VSIG-4, AND METHODS OF MAKING AND USING Filling date: 19 Aug 2020 Issue date: 25 Mar 2021	19 Aug 2020	25 Mar 2021
Grant	Grant Utility: Methods and kits for assaying endoglycosidase activity Filling date: 5 Oct 2017 Issue date: 12 Jan 2021	5 Oct 2017	12 Jan 2021
Application	Application COMPOUNDS THAT MODULATE THE INTERACTION OF VISTA AND VSIG3 AND METHODS OF MAKING AND USING Filling date: 1 Feb 2019 Issue date: 19 Nov 2020	1 Feb 2019	19 Nov 2020
Grant	Grant Utility: Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using Filling date: 26 Jun 2018 Issue date: 25 Aug 2020	26 Jun 2018	25 Aug 2020
Grant	Grant Utility: Dual chamber storage device Filling date: 30 Jul 2019 Issue date: 5 May 2020	30 Jul 2019	5 May 2020
Grant	Grant Utility: Dual chamber storage device Filling date: 12 Jun 2018 Issue date: 5 May 2020	12 Jun 2018	5 May 2020

Bio-Techne
Earnings Call Transcripts

Quarter	Transcript
Q3 2024 1 May 2024	Q3 2024 Earnings Call Transcript
Q2 2024 1 Feb 2024	Q2 2024 Earnings Call Transcript
Q1 2024 31 Oct 2023	Q1 2024 Earnings Call Transcript
Q4 2023 8 Aug 2023	Q4 2023 Earnings Call Transcript

TECH earnings call transcripts

Bio-Techne
Executives

Insider	Age	Compensation
Mr. Charles R. Kummeth (1960) Chief Executive Officer, Pres & Director	65	$4,690,000
Mr. James T. Hippel (1971) Executive Vice President of Fin. & Chief Financial Officer	54	$1,710,000
Mr. Norman David Eansor (1961) Advisor	64	$1,600,000
Mr. Kim Kelderman (1967) Pres of Diagnostics & Genomics	58	$1,450,000
Ms. Brenda S. Furlow J.D. (1958) Executive Vice President, Gen. Counsel, Sec. & Chief Compliance Officer	67	$1,270,000

Bio-Techne
Latest News

Monday, 23 December 2024
16:00	ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM	globenewswire.com
09:05	Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?	zacks.com
Friday, 20 December 2024
07:00	BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE	prnewswire.com
Thursday, 19 December 2024
12:10	YSX TECH. CO., LTD Announces Closing of Its Initial Public Offering and Full Exercise of Underwriter's Over-Allotment Option	globenewswire.com
07:00	BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT	prnewswire.com
Wednesday, 18 December 2024
07:00	ScaleReady awards a G-Rex® Grant to Moonlight Bio	prnewswire.com
Tuesday, 17 December 2024
17:18	YSX TECH. CO., LTD Announces Pricing of Its Initial Public Offering	globenewswire.com
Thursday, 12 December 2024
08:16	Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?	zacks.com
07:00	BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY	prnewswire.com
Tuesday, 10 December 2024
07:00	BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY	prnewswire.com
Monday, 2 December 2024
07:11	Should You Continue to Retain Bio-Techne Stock in Your Portfolio?	zacks.com
Friday, 29 November 2024
12:36	Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?	zacks.com
Wednesday, 27 November 2024
07:00	BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE	prnewswire.com
Monday, 25 November 2024
09:02	Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne	prnewswire.com
Friday, 22 November 2024
09:00	OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements	businesswire.com
Wednesday, 20 November 2024
07:00	BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES	prnewswire.com
Monday, 18 November 2024
07:00	BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH	prnewswire.com
Thursday, 14 November 2024
07:00	BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO	prnewswire.com
Monday, 11 November 2024
17:47	UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS	prnewswire.com
07:00	BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS	prnewswire.com
Friday, 8 November 2024
07:00	BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES	prnewswire.com
Thursday, 7 November 2024
07:00	ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy	prnewswire.com
Wednesday, 6 November 2024
07:00	BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING	prnewswire.com
Tuesday, 5 November 2024
07:00	LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH	prnewswire.com
Wednesday, 30 October 2024
15:48	Bio-Techne Corporation (TECH) Q1 2025 Earnings Call Transcript	seekingalpha.com
13:05	Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket	zacks.com
08:45	Techne (TECH) Beats Q1 Earnings and Revenue Estimates	zacks.com
07:49	Bio-Techne beats quarterly profit estimates, driven by diagnostic unit growth; shares rise	reuters.com
06:30	BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS	prnewswire.com
06:30	BIO-TECHNE DECLARES DIVIDEND	prnewswire.com

Ideas & Opinions

Seeking Alpha 15 Aug 2025

Bruker: Former Academia Customer Strength, Now Incredible Weakness
Seeking Alpha 8 Aug 2025

Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts
Seeking Alpha 6 Jun 2025

Bio-Techne: Slow Growth Amidst Healthcare Policy, MAHA Movement
Seeking Alpha 4 Apr 2024

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Seeking Alpha 20 Nov 2023

Bio-Techne: Quality Play Struggles But Looks More Compelling
Seeking Alpha 18 May 2023

Bio-Techne Corporation: Long-Term Quality, But At A Price
Seeking Alpha 6 Feb 2023

Charles River Laboratories International: A Great Business At A Decent Price
Seeking Alpha 11 Nov 2022

Bio-Techne: Recent Weakness, Charts Suggest It's Now A Buy (Technical Analysis)
Seeking Alpha 13 Jun 2021

The Stocks To Focus On Today
Seeking Alpha 10 Apr 2021

Bio-Techne: Stealth M&A Play Looking Rich Here

Frequently Asked Questions (FAQ)

What's the price of Bio-Techne stock today?

One share of Bio-Techne stock can currently be purchased for approximately $54.8.
When is Bio-Techne's next earnings date?

Unfortunately, Bio-Techne's (TECH) next earnings date is currently unknown.
Does Bio-Techne pay dividends?

Yes, Bio-Techne pays dividends and its trailing 12-month yield is 0.44% with 33% payout ratio. The last Bio-Techne stock dividend of $0.32 was paid on 25 Feb 2022.
How much money does Bio-Techne make?

Bio-Techne has a market capitalization of 11.47B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1.97% to 1.16B US dollars. Bio-Techne earned 168.11M US dollars in net income (profit) last year or $0.49 on an earnings per share basis.
What is Bio-Techne's stock symbol?

Bio-Techne Corporation is traded on the NASDAQ under the ticker symbol "TECH".
What is Bio-Techne's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Bio-Techne?

Shares of Bio-Techne can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Bio-Techne's key executives?
Bio-Techne's management team includes the following people:
- Mr. Charles R. Kummeth Chief Executive Officer, Pres & Director(age: 65, pay: $4,690,000)
- Mr. James T. Hippel Executive Vice President of Fin. & Chief Financial Officer(age: 54, pay: $1,710,000)
- Mr. Norman David Eansor Advisor(age: 64, pay: $1,600,000)
- Mr. Kim Kelderman Pres of Diagnostics & Genomics(age: 58, pay: $1,450,000)
- Ms. Brenda S. Furlow J.D. Executive Vice President, Gen. Counsel, Sec. & Chief Compliance Officer(age: 67, pay: $1,270,000)
How many employees does Bio-Techne have?

As Jul 2024, Bio-Techne employs 3,200 workers.
When Bio-Techne went public?

Bio-Techne Corporation is publicly traded company for more then 36 years since IPO on 9 Feb 1989.
What is Bio-Techne's official website?

The official website for Bio-Techne is bio-techne.com.
Where are Bio-Techne's headquarters?

Bio-Techne is headquartered at 614 McKinley Place N.E., Minneapolis, MN.
How can i contact Bio-Techne?

Bio-Techne's mailing address is 614 McKinley Place N.E., Minneapolis, MN and company can be reached via phone at +61 23798854.
What is Bio-Techne stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Bio-Techne in the last 12 months, the avarage price target is $82.33. The average price target represents a 50.24% change from the last price of $54.8.

Bio-Techne Corporation

bio-techne.com

Exchange:

NASDAQ

Full time employees:

3,100

Industry:

Biotechnology

Sector:

Healthcare

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

+61 23798854

614 McKinley Place N.E.
Minneapolis, MN 55413

CIK: 0000842023
ISIN: US09073M1045
CUSIP: 09073M104